news

Single antibody protects non-human primates from Ebola virus

Posted: 26 February 2016 | Victoria White | No comments yet

A single monoclonal antibody isolated from a human survivor of Ebola virus completely protected monkeys from lethal infection with the virus…

A single monoclonal antibody isolated from a human survivor of Ebola virus disease (EVD) completely protected monkeys from lethal infection with the virus, according to new research.

Importantly, the antibody, known as mAb114, was effective even when given five days after exposure to Ebola virus, suggesting that it could hold promise as a potential treatment for human cases of EVD.

Although several clinical trials are in progress, there are currently no licensed therapies against Ebola virus. Antibodies, or proteins produced by the immune system in response to infection, represent one possible approach to treating the disease.

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

In the study, investigators from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) administered a lethal dose of Zaire ebolavirus to rhesus macaques. After five days, the team treated three of the animals with daily intravenous injections of mAb114 for three consecutive days. All the treated animals survived and were free of EVD symptoms, while the untreated animal developed clinical signs of the disease.

The antibody was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), who discovered Ebola virus antibodies in blood samples from a survivor of the 1995 Ebola virus outbreak in Kikwit, Democratic Republic of the Congo. Investigators from the Institute for Research in Biomedicine in Switzerland isolated the specific antibodies to test for potential efficacy in treating Ebola virus infection.

First study to evaluate the efficacy of a single antibody against Ebola virus

According to John C. Trefry, Ph.D., of USAMRIID, a principal investigator, the study is the first to successfully evaluate a single antibody for efficacy against Ebola virus.

“While several antibody ‘cocktails’ have been tested, this is the first time we’ve evaluated a single antibody and demonstrated protection in nonhuman primates,” Trefry said, adding that having a single antibody could greatly simplify the development and regulatory approval process.

“This work highlights the importance of interagency collaboration,” commented Sina Bavari, Ph.D., USAMRIID’s science director. “The scientific community has learned a great deal from the largest Ebola outbreak in history. Combining our efforts is the best way to develop new medical countermeasures for prevention and treatment.”

Related topics

Related conditions

Leave a Reply

Your email address will not be published. Required fields are marked *